ArticleBMC nephrology2025
Efficacy of CD19-guided B-cell depletion with rituximab plus steroids in refractory focal segmental glomerulosclerosis.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveRefractory focal segmental glomerulosclerosis (FSGS) poses significant therapeutic challenges under conventional immunosuppressants. Although rituximab (RTX), an anti-CD20 monoclonal antibody, has demonstrated efficacy in nephrotic syndrome, its real-world effectiveness in adults with refractory FSGS remains unproven. STUDY
designWe retrospectively included 34 adults with biopsy-proven FSGS that was refractory to immunosuppressive regimens involving corticosteroids or calcineurin inhibitors, defined by persistent proteinuria > 3.5 g/day with < 50% reduction from baseline despite at least 4 months of therapy. Patients were grouped into either RTX combined with prednisone (RTX group, n = 16) or conventional non-RTX regimens (including prednisone, calcineurin inhibitors, cyclophosphamide, or their combinations; Conv group, n = 18). Rituximab was dosed to achieve peripheral B-cell depletion (CD19⁺ cell = 0/µL). Endpoints comprised complete remission (CR), overall response, relapse in initial responders, and relapse-free survival.
resultsThe patients were 44.4 ± 21.8 years old, with a median follow-up duration of 18.0 (10.6, 41.1) months. The baseline characteristics were comparable between groups, except that RTX group had a longer disease duration than Conv group (median 10.7 vs. 4.0 months, p = 0.046). The CR rate was 62.5% in RTX group and 33.3% in Conv group (p = 0.168), while the overall response rate was 75.0% in RTX group and 50.0% in Conv-group (p = 0.172). Among the responders, the median follow-up was 33.6 months in the Conv group and 36.1 months in the RTX group (p = 0.557). Responders in RTX group had a lower relapse rate compared to those in Conv group (25.0% vs. 77.8%, p = 0.030), and had a prolonged relapse-free survival (log-rank χ²=3.827, p = 0.050). There were 3 patients in RTX group relapsed, who achieved CR after repeat RTX therapy. No severe infusion reactions or opportunistic infections were observed in RTX group.
conclusionsRTX combining with prednisone was comparable in inducing remission for refractory FSGS patients and was associated with a significantly lower relapse rate and a strong trend towards prolonged relapse-free survival than conventional therapy. While heterogeneity exists, RTX may be a valuable therapeutic strategy for maintaining long-term disease control in responsive patients. CLINICAL TRAIL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.